$ZPTA
Zapata Computing Holdings Inc.

2024 Q2 Form 10-Q Financial Statement

#000119312524139464 Filed on May 15, 2024

View on sec.gov

Income Statement

Concept 2024 Q2 2024 Q1 2023 Q4
Revenue $2.001M $1.218M $1.329M
YoY Change
Cost Of Revenue $1.280M $1.052M $904.0K
YoY Change 11.3% -19.45%
Gross Profit $721.0K $166.0K $425.0K
YoY Change 155.67% -19.42%
Gross Profit Margin 36.03% 13.63% 31.98%
Selling, General & Admin $6.500M $3.835M $3.633M
YoY Change 120.56% 20.98%
% of Gross Profit 901.53% 2310.24% 854.82%
Research & Development $1.593M $1.407M $821.0K
YoY Change 8.37% -33.91%
% of Gross Profit 220.94% 847.59% 193.18%
Depreciation & Amortization $38.00K $34.00K
YoY Change -15.56%
% of Gross Profit 22.89% 8.0%
Operating Expenses $8.093M $5.242M $4.454M
YoY Change 514.19% 131.09% 859.31%
Operating Profit -$7.372M -$5.076M -$4.029M
YoY Change 459.48% 123.77%
Interest Expense $77.00K $784.0K -$40.00K
YoY Change -97.3% -69.08% -102.01%
% of Operating Profit
Other Income/Expense, Net -$8.197M -$17.24M -$3.671M
YoY Change -387.52% -779.87%
Pretax Income -$15.57M -$22.31M -$14.60M
YoY Change -1115.42% -8453.86% -1054.5%
Income Tax $7.000K $6.000K -$9.000K
% Of Pretax Income
Net Earnings -$15.58M -$22.32M -$14.60M
YoY Change -1115.88% -8456.17% -1053.91%
Net Earnings / Revenue -778.41% -1832.51% -1098.19%
Basic Earnings Per Share -$0.48 -$4.09
Diluted Earnings Per Share -$0.48 -$4.09 -$0.50
COMMON SHARES
Basic Shares Outstanding 31.98M 5.457M
Diluted Shares Outstanding 32.18M 5.457M

Balance Sheet

Concept 2024 Q2 2024 Q1 2023 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $7.251M $3.332M
YoY Change 1718.48% 440.8%
Cash & Equivalents $6.652M $6.037M $0.00
Short-Term Investments
Other Short-Term Assets $1.197M $323.0K
YoY Change 122.91% -45.34%
Inventory
Prepaid Expenses
Receivables $1.128M $1.938M
Other Receivables $0.00 $0.00
Total Short-Term Assets $11.01M $9.576M $205.5K
YoY Change 1299.23% 923.37% -82.97%
LONG-TERM ASSETS
Property, Plant & Equipment $106.0K $129.0K $156.0K
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $0.00 $0.00 $137.0K
YoY Change 459.87%
Total Long-Term Assets $174.0K $279.0K $86.27M
YoY Change -99.93% -99.88% -63.93%
TOTAL ASSETS
Total Short-Term Assets $11.01M $9.576M $205.5K
Total Long-Term Assets $174.0K $279.0K $86.27M
Total Assets $11.19M $9.855M $86.47M
YoY Change -95.44% -95.94% -64.03%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $11.58M $9.348M $6.452M
YoY Change
Accrued Expenses $5.576M $1.892M
YoY Change 528.34% 6134.35%
Deferred Revenue $736.0K $650.0K $744.0K
YoY Change 48.8%
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $2.428M
YoY Change
Total Short-Term Liabilities $22.90M $23.14M $955.8K
YoY Change 5350.03% 2502.92% 728.66%
LONG-TERM LIABILITIES
Long-Term Debt $2.191M $8.900M
YoY Change
Other Long-Term Liabilities $5.604M $0.00
YoY Change -38.57% -100.0%
Total Long-Term Liabilities $7.795M $8.900M
YoY Change -14.56% 8.4%
TOTAL LIABILITIES
Total Short-Term Liabilities $22.90M $23.14M $955.8K
Total Long-Term Liabilities $7.795M $8.900M
Total Liabilities $38.14M $8.159M $15.50M
YoY Change 251.98% -18.51% 86.13%
SHAREHOLDERS EQUITY
Retained Earnings -$127.4M -$111.8M -$15.29M
YoY Change 1167.84% 1132.22% 115.53%
Common Stock $4.000K $2.000K $0.00
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$26.96M -$21.08M -$15.29M
YoY Change
Total Liabilities & Shareholders Equity $11.19M $9.855M $86.47M
YoY Change -95.44% -95.94% -64.03%

Cashflow Statement

Concept 2024 Q2 2024 Q1 2023 Q4
OPERATING ACTIVITIES
Net Income -$15.58M -$22.32M -$14.60M
YoY Change -1115.88% -8456.17% -1053.91%
Depreciation, Depletion And Amortization $38.00K $34.00K
YoY Change -15.56%
Cash From Operating Activities -$2.147M -$2.378M
YoY Change 107.86% 1142.03%
INVESTING ACTIVITIES
Capital Expenditures $11.00K $0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$11.00K $0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 6.096M 2.389M
YoY Change 647.47%
NET CHANGE
Cash From Operating Activities -2.147M -2.378M
Cash From Investing Activities -11.00K 0.000
Cash From Financing Activities 6.096M 2.389M
Net Change In Cash 3.919M 11.00K
YoY Change -1902.87% -105.75%
FREE CASH FLOW
Cash From Operating Activities -$2.147M -$2.378M
Capital Expenditures $11.00K $0.00
Free Cash Flow -$2.158M -$2.378M
YoY Change 108.92%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q4 us-gaap Assets
Assets
8067000
CY2024Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
9348000
CY2024Q1 dei Amendment Flag
AmendmentFlag
false
CY2024Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2024Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2024Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001843714
CY2024Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
CY2024Q1 dei Document Type
DocumentType
10-Q
CY2024Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2024Q1 dei Document Period End Date
DocumentPeriodEndDate
2024-03-31
CY2024Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
CY2024Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2024Q1 dei Entity File Number
EntityFileNumber
001-41218
CY2024Q1 dei Entity Registrant Name
EntityRegistrantName
Zapata Computing Holdings Inc.
CY2024Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2024Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
98-1578373
CY2024Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
100 Federal Street, Floor 20
CY2024Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Boston
CY2024Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02110
CY2024Q1 dei City Area Code
CityAreaCode
844
CY2024Q1 dei Local Phone Number
LocalPhoneNumber
492-7282
CY2024Q1 dei Security12b Title
Security12bTitle
Common Stock
CY2024Q1 dei Trading Symbol
TradingSymbol
ZPTA
CY2024Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2024Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2024Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2024Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2024Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2024Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2024Q1 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2024Q1 dei Entity Shell Company
EntityShellCompany
false
CY2024Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
31982816
CY2024Q1 us-gaap Cash
Cash
7251000
CY2023Q4 us-gaap Cash
Cash
3332000
CY2024Q1 us-gaap Receivables Net Current
ReceivablesNetCurrent
1128000
CY2023Q4 us-gaap Receivables Net Current
ReceivablesNetCurrent
1938000
CY2024Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1197000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
323000
CY2024Q1 us-gaap Assets Current
AssetsCurrent
9576000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
5593000
CY2024Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
129000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
156000
CY2024Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
150000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
238000
CY2024Q1 wnnr Deferred Offering Costs Non Current
DeferredOfferingCostsNonCurrent
0
CY2023Q4 wnnr Deferred Offering Costs Non Current
DeferredOfferingCostsNonCurrent
1943000
CY2024Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
0
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
137000
CY2024Q1 us-gaap Assets
Assets
9855000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
6452000
CY2024Q1 wnnr Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
5535000
CY2023Q4 wnnr Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
1945000
CY2024Q1 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
650000
CY2023Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
744000
CY2024Q1 wnnr Deferred Legal Fees Current
DeferredLegalFeesCurrent
3330000
CY2023Q4 wnnr Deferred Legal Fees Current
DeferredLegalFeesCurrent
0
CY2024Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
161000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
252000
CY2024Q1 wnnr Notes Payable Related Parties Current
NotesPayableRelatedPartiesCurrent
2428000
CY2023Q4 wnnr Notes Payable Related Parties Current
NotesPayableRelatedPartiesCurrent
0
CY2024Q1 us-gaap Lines Of Credit Current
LinesOfCreditCurrent
1688000
CY2023Q4 us-gaap Lines Of Credit Current
LinesOfCreditCurrent
0
CY2024Q1 us-gaap Liabilities Current
LiabilitiesCurrent
23140000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
9393000
CY2024Q1 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
4935000
CY2023Q4 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
0
CY2024Q1 us-gaap Senior Long Term Notes
SeniorLongTermNotes
2000000
CY2023Q4 us-gaap Senior Long Term Notes
SeniorLongTermNotes
8900000
CY2024Q1 wnnr Long Term Notes Payable To Related Parities
LongTermNotesPayableToRelatedParities
191000
CY2023Q4 wnnr Long Term Notes Payable To Related Parities
LongTermNotesPayableToRelatedParities
0
CY2024Q1 wnnr Non Current Liabilities
NonCurrentLiabilities
669000
CY2023Q4 wnnr Non Current Liabilities
NonCurrentLiabilities
0
CY2024Q1 us-gaap Liabilities
Liabilities
30935000
CY2023Q4 us-gaap Liabilities
Liabilities
18293000
CY2024Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2024Q1 us-gaap Redeemable Noncontrolling Interest Equity Preferred Carrying Amount
RedeemableNoncontrollingInterestEquityPreferredCarryingAmount
0
CY2023Q4 us-gaap Redeemable Noncontrolling Interest Equity Preferred Carrying Amount
RedeemableNoncontrollingInterestEquityPreferredCarryingAmount
64716000
CY2024Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
600000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
23500000
CY2024Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
29123701
CY2024Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
29123701
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
4678950
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
4678950
CY2024Q1 us-gaap Common Stock Value
CommonStockValue
2000
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
0
CY2024Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
90828000
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
14633000
CY2024Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-64000
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-49000
CY2024Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-111846000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-89526000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
-21080000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-74942000
CY2024Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
9855000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
8067000
CY2024Q1 us-gaap Revenues
Revenues
1218000
CY2023Q1 us-gaap Revenues
Revenues
1512000
CY2024Q1 us-gaap Cost Of Revenue
CostOfRevenue
1052000
CY2023Q1 us-gaap Cost Of Revenue
CostOfRevenue
1306000
CY2024Q1 us-gaap Gross Profit
GrossProfit
166000
CY2023Q1 us-gaap Gross Profit
GrossProfit
206000
CY2024Q1 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
1629000
CY2023Q1 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
1701000
CY2024Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1407000
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2129000
CY2024Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2206000
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1469000
CY2024Q1 us-gaap Operating Expenses
OperatingExpenses
5242000
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
5299000
CY2024Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-5076000
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-5093000
CY2024Q1 us-gaap Interest Expense
InterestExpense
784000
CY2023Q1 us-gaap Interest Expense
InterestExpense
0
CY2024Q1 us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
-4935000
CY2023Q1 us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
0
CY2024Q1 us-gaap Induced Conversion Of Convertible Debt Expense
InducedConversionOfConvertibleDebtExpense
9776000
CY2023Q1 us-gaap Induced Conversion Of Convertible Debt Expense
InducedConversionOfConvertibleDebtExpense
0
CY2024Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1743000
CY2023Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
29000
CY2024Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-17238000
CY2023Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
29000
CY2024Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-22314000
CY2023Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-5064000
CY2024Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
6000
CY2023Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
4000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-22320000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-5068000
CY2024Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-4.09
CY2024Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-4.09
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.09
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.09
CY2024Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
5457386
CY2024Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
5457386
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
4657228
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
4657228
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-22320000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-5068000
CY2024Q1 wnnr Foreign Currency Translation Adjustment
ForeignCurrencyTranslationAdjustment
-15000
CY2023Q1 wnnr Foreign Currency Translation Adjustment
ForeignCurrencyTranslationAdjustment
-1000
CY2024Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-22335000
CY2023Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-5069000
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-57083000
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
6000
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
45000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-5068000
CY2023Q1 us-gaap Cumulative Translation Adjustment Net Of Tax Period Increase Decrease
CumulativeTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease
-1000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-62101000
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-74942000
CY2024Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
68000
CY2024Q1 us-gaap Share Based Compensation
ShareBasedCompensation
191000
CY2024Q1 us-gaap Gain Loss On Repurchase Of Debt Instrument
GainLossOnRepurchaseOfDebtInstrument
9776000
CY2024Q1 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
14660000
CY2024Q1 us-gaap Reclassifications Of Temporary To Permanent Equity
ReclassificationsOfTemporaryToPermanentEquity
64716000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-22320000
CY2024Q1 us-gaap Cumulative Translation Adjustment Net Of Tax Period Increase Decrease
CumulativeTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease
-15000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
-21080000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-22320000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-5068000
CY2024Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
38000
CY2023Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
45000
CY2024Q1 us-gaap Paid In Kind Interest
PaidInKindInterest
761000
CY2023Q1 us-gaap Paid In Kind Interest
PaidInKindInterest
0
CY2024Q1 wnnr Non Cash Vendor Payments
NonCashVendorPayments
150000
CY2023Q1 wnnr Non Cash Vendor Payments
NonCashVendorPayments
0
CY2024Q1 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-9776000
CY2023Q1 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0
CY2024Q1 us-gaap Share Based Compensation
ShareBasedCompensation
191000
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
45000
CY2024Q1 wnnr Non Cash Lease Expense
NonCashLeaseExpense
87000
CY2023Q1 wnnr Non Cash Lease Expense
NonCashLeaseExpense
87000
CY2024Q1 wnnr Equity Line Of Credit Commitment Expense
EquityLineOfCreditCommitmentExpense
1688000
CY2023Q1 wnnr Equity Line Of Credit Commitment Expense
EquityLineOfCreditCommitmentExpense
0
CY2024Q1 us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
-4935000
CY2023Q1 us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
0
CY2024Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-809000
CY2023Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-458000
CY2024Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
736000
CY2023Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
589000
CY2024Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2109000
CY2023Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
635000
CY2024Q1 wnnr Increase Decrease In Accrued Expenses Other Current Liabilities And Other Non Current Liabilities
IncreaseDecreaseInAccruedExpensesOtherCurrentLiabilitiesAndOtherNonCurrentLiabilities
550000
CY2023Q1 wnnr Increase Decrease In Accrued Expenses Other Current Liabilities And Other Non Current Liabilities
IncreaseDecreaseInAccruedExpensesOtherCurrentLiabilitiesAndOtherNonCurrentLiabilities
-517000
CY2024Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-94000
CY2023Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-330000
CY2024Q1 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-91000
CY2023Q1 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-90000
CY2024Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2147000
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-5324000
CY2024Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
11000
CY2023Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
0
CY2024Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-11000
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0
CY2024Q1 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
1500000
CY2023Q1 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
0
CY2024Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
68000
CY2023Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
6000
CY2024Q1 wnnr Proceeds From Reverse Recapitalization
ProceedsFromReverseRecapitalization
12636000
CY2023Q1 wnnr Proceeds From Reverse Recapitalization
ProceedsFromReverseRecapitalization
0
CY2024Q1 wnnr Prepayment For Forward Purchase Agreement
PrepaymentForForwardPurchaseAgreement
10986000
CY2023Q1 wnnr Prepayment For Forward Purchase Agreement
PrepaymentForForwardPurchaseAgreement
0
CY2024Q1 us-gaap Proceeds From Issuance Of Senior Long Term Debt
ProceedsFromIssuanceOfSeniorLongTermDebt
5878000
CY2023Q1 us-gaap Proceeds From Issuance Of Senior Long Term Debt
ProceedsFromIssuanceOfSeniorLongTermDebt
0
CY2024Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
6096000
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
6000
CY2024Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-19000
CY2023Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
5000
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
3919000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-5313000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
3469000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
10210000
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
7388000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4897000
CY2024Q1 us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
14660000
CY2023Q1 us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
0
CY2024Q1 wnnr Issuance Of Common Stock In Connection With Debt Issuance Costs Related To Senior Secured Notes And Capital Markets Advisory Agreements
IssuanceOfCommonStockInConnectionWithDebtIssuanceCostsRelatedToSeniorSecuredNotesAndCapitalMarketsAdvisoryAgreements
352000
CY2023Q1 wnnr Issuance Of Common Stock In Connection With Debt Issuance Costs Related To Senior Secured Notes And Capital Markets Advisory Agreements
IssuanceOfCommonStockInConnectionWithDebtIssuanceCostsRelatedToSeniorSecuredNotesAndCapitalMarketsAdvisoryAgreements
0
CY2024Q1 us-gaap Notes Issued1
NotesIssued1
1150000
CY2023Q1 us-gaap Notes Issued1
NotesIssued1
0
CY2024Q1 wnnr Deferred Offering Costs Included In Accounts Payable And Accrued Expenses And Other Current Liabilities
DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpensesAndOtherCurrentLiabilities
4222000
CY2023Q1 wnnr Deferred Offering Costs Included In Accounts Payable And Accrued Expenses And Other Current Liabilities
DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpensesAndOtherCurrentLiabilities
0
CY2024Q1 wnnr Debt Issuance Costs Incurred And Included In Accrued Expenses And Other Current Liabilities
DebtIssuanceCostsIncurredAndIncludedInAccruedExpensesAndOtherCurrentLiabilities
35000
CY2023Q1 wnnr Debt Issuance Costs Incurred And Included In Accrued Expenses And Other Current Liabilities
DebtIssuanceCostsIncurredAndIncludedInAccruedExpensesAndOtherCurrentLiabilities
0
CY2024Q1 wnnr Temporary Equity Converted Into Permanent Equity Upon Recapitalization
TemporaryEquityConvertedIntoPermanentEquityUponRecapitalization
64716000
CY2023Q1 wnnr Temporary Equity Converted Into Permanent Equity Upon Recapitalization
TemporaryEquityConvertedIntoPermanentEquityUponRecapitalization
0
CY2024Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-22320000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-5068000
CY2024Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-111846000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-89526000
CY2024Q1 us-gaap Use Of Estimates
UseOfEstimates
<div style="margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Use of Estimates </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The preparation of the Company’s unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the unaudited condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. Significant estimates and assumptions reflected within these condensed consolidated financial statements include, but are not limited to, revenue recognition, the Forward Purchase Agreement derivative liability, the valuation of the Company’s common stock, and stock-based awards. The Company’s estimates are based on historical information available as of the date of the unaudited condensed consolidated financial statements and various other assumptions that the Company believes are reasonable under the circumstances. Actual results may differ materially from those estimates <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">or assumptions. </div></div></div>
CY2024Q1 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Concentrations of Credit Risk </div></div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Financial instruments that subject the Company to credit risk consist primarily of cash and cash equivalents and accounts receivable. The Company maintains its cash and cash equivalents at high-quality and accredited financial institutions. </div></div><br/></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 9pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;display:inline;">The Company<div style="letter-spacing: 0px; top: 0px;display:inline;"> </div></div></div><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;display:inline;">performs ongoing credit evaluations of its customers and generally requires no collateral to secure accounts receivable. Accounts receivable is presented after consideration of an allowance for credit losses, which is an estimate of amounts that may not be collectible. In determining the amount of the allowance at each reporting date, the Company makes judgments about general economic conditions, historical <div style="white-space: nowrap; letter-spacing: 0px; top: 0px; line-height: 9pt;display:inline;">write-off</div> experience and any specific risks identified in customer collection matters, including the aging of unpaid accounts receivable and changes in customer financial conditions. Account balances are written off after all means of collection are exhausted and the potential for recovery is determined to not be probable. As of March 31, 2024 and December 31, 2023, the Company recorded zero</div><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;display:inline;"> allowance for credit losses.</div></div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;display:inline;">As of March 31, 2024, the Company’s accounts receivable was from three main customers, representing approximately </div><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;display:inline;">62</div><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;display:inline;">%, </div><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;display:inline;">26</div><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;display:inline;">% and </div><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;display:inline;">12</div><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;display:inline;">% of the Company’s total accounts receivable, of which </div><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;display:inline;">62</div><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;display:inline;">% is from a related party. As of December 31, 2023, the Company’s accounts receivable was from three main customers, representing approximately </div><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;display:inline;">43</div><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;display:inline;">%, </div><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;display:inline;">31</div><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;display:inline;">% and </div><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;display:inline;">26</div><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;display:inline;">% of the Company’s total accounts receivable, of which 43% is from a related party. </div></div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;display:inline;">For the three months ended March 31, 2024, the Company had four customers that represented greater than 10% of the Company’s total revenue and revenue recognized from these customers represented approximately </div><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;display:inline;">36</div><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;display:inline;">%, </div><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;display:inline;">22</div><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;display:inline;">%, </div><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;display:inline;">20</div><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;display:inline;">% and </div><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;display:inline;">14</div><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;display:inline;">% of total revenue, of which </div><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;display:inline;">36</div><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;display:inline;">% is from a related party. For the three months ended March 31, 2023, the Company had four customers that represented greater than 10% of the Company’s total revenue and revenue recognized from these customers represented approximately </div><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;display:inline;">33</div><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;display:inline;">%, </div><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;display:inline;">27</div><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;display:inline;">%, </div><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;display:inline;">21</div><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;display:inline;">% and </div><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;display:inline;">19</div><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;display:inline;">% of total revenue, of which 33% is from a related party. </div></div>
CY2023Q4 us-gaap Financing Receivable Allowance For Credit Losses
FinancingReceivableAllowanceForCreditLosses
0
CY2024Q1 us-gaap Financing Receivable Allowance For Credit Losses
FinancingReceivableAllowanceForCreditLosses
0
CY2024Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6037000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2693000
CY2023Q4 wnnr Restircted Cash Deposit To Secure Letter Of Credit
RestirctedCashDepositToSecureLetterOfCredit
137000
CY2024Q1 wnnr Restircted Cash Deposit To Secure Letter Of Credit
RestirctedCashDepositToSecureLetterOfCredit
137000
CY2024Q1 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
7251000
CY2023Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
3332000
CY2024Q1 us-gaap Restricted Cash Equivalents
RestrictedCashEquivalents
137000
CY2023Q4 us-gaap Restricted Cash Equivalents
RestrictedCashEquivalents
137000
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
7388000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
3469000
CY2024Q1 wnnr Deferred Offering Costs Non Current
DeferredOfferingCostsNonCurrent
0
CY2023Q4 wnnr Deferred Offering Costs Non Current
DeferredOfferingCostsNonCurrent
1943000
CY2024Q1 us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
0
CY2023 us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
0
CY2024Q1 us-gaap Provision For Loss On Contracts
ProvisionForLossOnContracts
0
CY2023Q4 us-gaap Provision For Loss On Contracts
ProvisionForLossOnContracts
0
CY2024Q1 us-gaap Capitalized Contract Cost Net
CapitalizedContractCostNet
29000
CY2023Q4 us-gaap Capitalized Contract Cost Net
CapitalizedContractCostNet
38000
CY2024Q1 us-gaap Amortization Of Acquisition Costs
AmortizationOfAcquisitionCosts
10000
CY2023Q1 us-gaap Amortization Of Acquisition Costs
AmortizationOfAcquisitionCosts
4000
CY2024Q1 us-gaap Contract With Customer Receivable After Allowance For Credit Loss Current
ContractWithCustomerReceivableAfterAllowanceForCreditLossCurrent
910000
CY2023Q4 us-gaap Contract With Customer Receivable After Allowance For Credit Loss Current
ContractWithCustomerReceivableAfterAllowanceForCreditLossCurrent
1341000
CY2024Q1 us-gaap Unbilled Receivables Current
UnbilledReceivablesCurrent
218000
CY2023Q4 us-gaap Unbilled Receivables Current
UnbilledReceivablesCurrent
597000
CY2024Q1 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
650000
CY2023Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
744000
CY2023Q4 us-gaap Contract With Customer Receivable After Allowance For Credit Loss Current
ContractWithCustomerReceivableAfterAllowanceForCreditLossCurrent
1341000
CY2022Q4 us-gaap Contract With Customer Receivable After Allowance For Credit Loss Current
ContractWithCustomerReceivableAfterAllowanceForCreditLossCurrent
600000
CY2023Q4 us-gaap Unbilled Receivables Current
UnbilledReceivablesCurrent
597000
CY2022Q4 us-gaap Unbilled Receivables Current
UnbilledReceivablesCurrent
827000
CY2023Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
744000
CY2022Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
500000
CY2024Q1 us-gaap Income Tax Examination Penalties And Interest Accrued
IncomeTaxExaminationPenaltiesAndInterestAccrued
0
CY2023Q4 us-gaap Income Tax Examination Penalties And Interest Accrued
IncomeTaxExaminationPenaltiesAndInterestAccrued
0
CY2024Q1 wnnr Stock Issued During The Period Shares Restructuring
StockIssuedDuringThePeriodSharesRestructuring
17696425
CY2024Q1 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
3016409
CY2024Q1 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.9141
CY2024Q1 wnnr Percentage Of Aggregate Shares Held By The Existing Shareholders
PercentageOfAggregateSharesHeldByTheExistingShareholders
0.63
CY2024Q1 wnnr Number Of Directors
NumberOfDirectors
7
CY2024Q1 wnnr Number Of Independent Directors
NumberOfIndependentDirectors
1
CY2024Q1 us-gaap Payments For Merger Related Costs
PaymentsForMergerRelatedCosts
7058000
CY2024Q1 us-gaap Payments For Merger Related Costs
PaymentsForMergerRelatedCosts
150000
CY2024Q1 us-gaap Stock Issued During Period Shares Conversion Of Units
StockIssuedDuringPeriodSharesConversionOfUnits
33333
CY2024Q1 wnnr Reduction In Additional Paid In Capital In The Account Of Capital Market Advisory
ReductionInAdditionalPaidInCapitalInTheAccountOfCapitalMarketAdvisory
450000
CY2024Q1 us-gaap Stock Issued During Period Shares Issued For Services
StockIssuedDuringPeriodSharesIssuedForServices
33333
CY2024Q1 wnnr Cash Payment To Third Party
CashPaymentToThirdParty
1800000
CY2024Q1 wnnr Payment Of Date
PaymentOfDate
of $113 commencing on the earlier of May 31, 2024
CY2024Q1 wnnr Payment Of Condition Amount
PaymentOfConditionAmount
300000
CY2024Q1 wnnr Voluntarily Payment To Third Party
VoluntarilyPaymentToThirdParty
1500000
CY2024Q1 wnnr Payment For Consummation Of A Financing Transaction
PaymentForConsummationOfAFinancingTransaction
1800000
CY2024Q1 wnnr Proceeds From Consummation Of A Financing Transaction
ProceedsFromConsummationOfAFinancingTransaction
15000000
CY2024Q1 wnnr Merger Recognized As Transaction Cost
MergerRecognizedAsTransactionCost
1800000
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
784000
CY2024Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
665000
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
628000
CY2024Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
129000
CY2024Q1 us-gaap Liabilities
Liabilities
8159000
CY2024Q1 us-gaap Accounts Payable Current And Noncurrent
AccountsPayableCurrentAndNoncurrent
223000
CY2024Q1 us-gaap Accrued Liabilities Current And Noncurrent
AccruedLiabilitiesCurrentAndNoncurrent
1987000
CY2024Q1 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
2619000
CY2024Q1 us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
-4935000
CY2024Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
794000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
156000
CY2024Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
38000
CY2023 us-gaap Depreciation And Amortization
DepreciationAndAmortization
45000
CY2024Q1 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
710000
CY2023Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
263000
CY2024Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
4705000
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1377000
CY2024Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
120000
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
305000
CY2024Q1 wnnr Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
5535000
CY2023Q4 wnnr Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
1945000
CY2024Q1 wnnr Subscription Receivable From Recycled Shares
SubscriptionReceivableFromRecycledShares
10986000
CY2024Q1 us-gaap Senior Long Term Notes
SeniorLongTermNotes
2000000
CY2023Q4 us-gaap Senior Long Term Notes
SeniorLongTermNotes
8900000
CY2024Q1 wnnr Notes Payable To Related Parties Current And Current
NotesPayableToRelatedPartiesCurrentAndCurrent
2619000
CY2023Q4 wnnr Notes Payable To Related Parties Current And Current
NotesPayableToRelatedPartiesCurrentAndCurrent
0
CY2024Q1 us-gaap Debt Longterm And Shortterm Combined Amount
DebtLongtermAndShorttermCombinedAmount
4619000
CY2023Q4 us-gaap Debt Longterm And Shortterm Combined Amount
DebtLongtermAndShorttermCombinedAmount
8900000
CY2024Q1 wnnr Notes Payable Related Parties Current
NotesPayableRelatedPartiesCurrent
2428000
CY2023Q4 wnnr Notes Payable Related Parties Current
NotesPayableRelatedPartiesCurrent
0
CY2024Q1 us-gaap Debt Current
DebtCurrent
2428000
CY2023Q4 us-gaap Debt Current
DebtCurrent
0
CY2024Q1 wnnr Note Payable Related Parties Non Current
NotePayableRelatedPartiesNonCurrent
191000
CY2023Q4 wnnr Note Payable Related Parties Non Current
NotePayableRelatedPartiesNonCurrent
0
CY2024Q1 us-gaap Senior Long Term Notes
SeniorLongTermNotes
2000000
CY2023Q4 us-gaap Senior Long Term Notes
SeniorLongTermNotes
8900000
CY2024Q1 us-gaap Long Term Debt
LongTermDebt
2191000
CY2023Q4 us-gaap Long Term Debt
LongTermDebt
8900000
CY2024Q1 us-gaap Debt Longterm And Shortterm Combined Amount
DebtLongtermAndShorttermCombinedAmount
4619000
CY2023Q4 us-gaap Debt Longterm And Shortterm Combined Amount
DebtLongtermAndShorttermCombinedAmount
8900000
CY2023Q4 us-gaap Senior Notes
SeniorNotes
8900000
CY2023Q4 us-gaap Unamortized Debt Issuance Expense
UnamortizedDebtIssuanceExpense
158000
CY2024Q1 wnnr Senior Secured Notes And Notes Payable To Related Party Future Minimum Payments Due Current Remainder Of Fiscal Year
SeniorSecuredNotesAndNotesPayableToRelatedPartyFutureMinimumPaymentsDueCurrentRemainderOfFiscalYear
1891000
CY2024Q1 wnnr Senior Secured Notes And Notes Payable To Related Party Future Minimum Payments Due In Next Twelve Months
SeniorSecuredNotesAndNotesPayableToRelatedPartyFutureMinimumPaymentsDueInNextTwelveMonths
796000
CY2024Q1 wnnr Senior Secured Notes And Notes Payable To Related Party Future Minimum Payments Due In Two Years
SeniorSecuredNotesAndNotesPayableToRelatedPartyFutureMinimumPaymentsDueInTwoYears
2000000
CY2024Q1 wnnr Senior Secured Notes And Notes Payable To Related Party Future Minimum Payments Due
SeniorSecuredNotesAndNotesPayableToRelatedPartyFutureMinimumPaymentsDue
4687000
CY2024Q1 wnnr Payable Imputed Interest
PayableImputedInterest
-68000
CY2024Q1 us-gaap Debt Longterm And Shortterm Combined Amount
DebtLongtermAndShorttermCombinedAmount
4619000
CY2024Q1 wnnr Temporary Equity Conversion Into Permanent Equity Exchange Ratio
TemporaryEquityConversionIntoPermanentEquityExchangeRatio
0.9141
CY2024Q1 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
14222580
CY2024Q1 wnnr Decrease In Temporary Equity Due To Conversion Into Permanent Equity Shares
DecreaseInTemporaryEquityDueToConversionIntoPermanentEquityShares
13001114
CY2024Q1 wnnr Temporary Equity Conversion Into Permanent Equity Exchange Ratio
TemporaryEquityConversionIntoPermanentEquityExchangeRatio
0.9141
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
14647823
CY2023Q4 wnnr Preferred Stock Share Issued And Outstanding
PreferredStockShareIssuedAndOutstanding
13001114
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
64716000
CY2023Q4 us-gaap Preferred Stock Liquidation Preference Value
PreferredStockLiquidationPreferenceValue
65004000
CY2023 us-gaap Stock Issued During Period Shares Conversion Of Convertible Securities
StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
13001114
CY2024Q1 us-gaap Proceeds From Issuance Of Convertible Preferred Stock
ProceedsFromIssuanceOfConvertiblePreferredStock
50000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
23500000
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Other Shares Outstanding
CommonStockOtherSharesOutstanding
3276076
CY2024Q1 us-gaap Convertible Preferred Stock Shares Issued Upon Conversion
ConvertiblePreferredStockSharesIssuedUponConversion
13001114
CY2024Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
30822000
CY2024Q1 wnnr Class Of Warrants Or Rights Period After Which The Warrants Or Rights Are Exercisable
ClassOfWarrantsOrRightsPeriodAfterWhichTheWarrantsOrRightsAreExercisable
P30D
CY2024Q1 wnnr Reserve For Common Stock Issuance
ReserveForCommonStockIssuance
3491146
CY2024Q1 wnnr Percentage Of Common Stock Share Outstanding
PercentageOfCommonStockShareOutstanding
0.05
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3078475
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
2.38
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y11M23D
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
4489000
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0
CY2024Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0
CY2024Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
47183
CY2024Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.44
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
112743
CY2024Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
2.49
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2918549
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
2.39
CY2024Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y10M6D
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
32696000
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
2090219
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
2.03
CY2024Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
P6Y3M7D
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
24182000
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
2918549
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
2.39
CY2024Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P6Y10M6D
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
32696000
CY2024Q1 us-gaap Deferred Compensation Arrangement With Individual Allocated Share Based Compensation Expense
DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense
1058000
CY2024Q1 wnnr Unrecognized Compensation Remaining Weighted Average Period
UnrecognizedCompensationRemainingWeightedAveragePeriod
P1Y5M19D
CY2024Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
191000
CY2023Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
45000
CY2024Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares
1129630
CY2024Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P3Y
CY2024Q1 wnnr Aggregate Number Of Trading Days For Determining The Share Price
AggregateNumberOfTradingDaysForDeterminingTheSharePrice
P20D
CY2024Q1 wnnr Number Of Consecutive Trading Days For Determining The Share Price
NumberOfConsecutiveTradingDaysForDeterminingTheSharePrice
P30D
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
P3Y
CY2024Q1 wnnr Percentage Of Fair Market Value Per Share
PercentageOfFairMarketValuePerShare
0.85
CY2024Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
91000
CY2023Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
101000
CY2024Q1 us-gaap Short Term Lease Cost
ShortTermLeaseCost
3000
CY2023Q1 us-gaap Short Term Lease Cost
ShortTermLeaseCost
0
CY2024Q1 us-gaap Lease Cost
LeaseCost
94000
CY2023Q1 us-gaap Lease Cost
LeaseCost
101000
CY2024Q1 us-gaap Variable Lease Cost
VariableLeaseCost
0
CY2023Q1 us-gaap Variable Lease Cost
VariableLeaseCost
0
CY2024Q1 us-gaap Operating Lease Lease Income Lease Payments
OperatingLeaseLeaseIncomeLeasePayments
96000
CY2023Q1 us-gaap Operating Lease Lease Income Lease Payments
OperatingLeaseLeaseIncomeLeasePayments
103000
CY2024Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P0Y6M
CY2023Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y4M24D
CY2024Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.1128
CY2023Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.1152
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
165000
CY2024Q1 wnnr Lessee Operating Lease Liability Payments After Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsAfterRemainderOfFiscalYear
0
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
165000
CY2024Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
4000
CY2024Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
161000
CY2024Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-4.09
CY2024Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-4.09
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.09
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.09
CY2024Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
6000
CY2023Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
4000
CY2024Q1 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2024Q1 wnnr Non Refundable Cash Fee Payable Over The Term To Related Party
NonRefundableCashFeePayableOverTheTermToRelatedParty
113000
CY2024Q1 wnnr Deferred Payment Of Other Agreements And Amendments
DeferredPaymentOfOtherAgreementsAndAmendments
5163000
CY2024Q1 us-gaap Other Commitment Due In Next Twelve Months
OtherCommitmentDueInNextTwelveMonths
5093000
CY2024Q1 us-gaap Other Commitment Due In Second Year
OtherCommitmentDueInSecondYear
2120000
CY2024Q1 us-gaap Other Commitment
OtherCommitment
7213000
CY2024Q1 wnnr Agreement Periods
AgreementPeriods
P24M
CY2024Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
5457386
CY2024Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
5457386
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
4657228
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
4657228
CY2024Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
29336162
CY2023Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
15670438

Files In Submission

Name View Source Status
d822296d10q_htm.xml Edgar Link completed
0001193125-24-139464-index-headers.html Edgar Link pending
0001193125-24-139464-index.html Edgar Link pending
0001193125-24-139464.txt Edgar Link pending
0001193125-24-139464-xbrl.zip Edgar Link pending
d822296d10q.htm Edgar Link pending
d822296dex311.htm Edgar Link pending
d822296dex312.htm Edgar Link pending
d822296dex321.htm Edgar Link pending
d822296dex322.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R76.htm Edgar Link pending
R77.htm Edgar Link pending
R78.htm Edgar Link pending
R79.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
wnnr-20240331.xsd Edgar Link pending
wnnr-20240331_def.xml Edgar Link unprocessable
wnnr-20240331_lab.xml Edgar Link unprocessable
wnnr-20240331_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
wnnr-20240331_cal.xml Edgar Link unprocessable